{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:05:51Z","timestamp":1790867151885,"version":"4.1.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Even with early antituberculosis (TB) treatment, some patients with pulmonary TB (PTB) may experience progression of chest computed tomography (CT) lesions. However, there is limited information on the causes and management of this progression during treatment. This study was undertaken to improve clinical understanding of the various causes and management strategies for the worsening of chest CT lesions in patients with PTB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective analysis was performed on the medical records of 61 PTB patients. We evaluated the radiological features, clinical characteristics, laboratory findings, causes, and management of chest CT lesions progression in PTB during anti-TB treatment and compared the characteristics of patients in the paradoxical response (PR) group and the non-PR group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The most common cause of the chest CT progression lesions was PR, accounting for 50.8% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 31) of the cases. Other important causes included insufficient anti-TB treatment (21.3%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 13), drug-resistant TB (8.2%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 5), and comorbidities such as bacterial infections (8.2%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 5), fungal infections (6.6%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 4), and lung cancer (4.9%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 3). Patients with PR were primarily treated by continuing their anti-TB management, whereas those with non-PR due to other causes received treatment targeting the underlying etiology. PR patients were younger (Mann\u2013Whitney\n                      <jats:italic toggle=\"yes\">U<\/jats:italic>\n                      -test,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001; 95% confidence interval [CI]: 15.8\u201332.2)., had more asymptomatic cases (74.2% vs. 4.0%; \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      test,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001; odds ratio [OR]: 64.3, 95% CI: 12.5\u2013330.2), showed higher Mycobacterium TB culture positivity (64.5% vs. 30.0%; \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      test,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.015; OR: 4.2, 95% CI: 1.4\u201312.6), and had quicker lesion progression than the non-PR group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004; 95% CI: 1.0\u20133.0).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>PR is the major cause of chest CT lesion progression in PTB during anti-TB. Continuation of anti-TB therapy can promote the absorption of lesions. Differences between PR and non-PR patients can help clinicians in diagnosing and guiding treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_33_25","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T15:00:35Z","timestamp":1750431635000},"page":"145-152","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Causes and Management of Chest Computed Tomography Lesions Progression in Pulmonary Tuberculosis during Antituberculosis Treatment"],"prefix":"10.4103","volume":"14","author":[{"given":"Shuangyin","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Chongqing Emergency Medical Center, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuiliang","family":"Yang","sequence":"additional","affiliation":[{"name":"The First Clinical College of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Pu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3231-7758","authenticated-orcid":false,"given":"Pu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"R2-20260422","first-page":"234","article-title":"Comprehensive interpretation of the classification of tuberculosis (WS 196-2017)","volume":"40","author":"Er-Yong","year":"2018","journal-title":"Chin J Antituberculosis"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.21037\/qims-23-1223","article-title":"Chinese expert consensus on imaging diagnosis of drug-resistant pulmonary tuberculosis","volume":"14","author":"Xu","year":"2024","journal-title":"Quant Imaging Med Surg"},{"key":"R4-20260422","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jinf.2009.05.006","article-title":"Paradoxical responses in non-HIV-infected patients with peripheral lymph node tuberculosis","volume":"59","author":"Cho","year":"2009","journal-title":"J Infect"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10096-002-0821-2","article-title":"Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients","volume":"21","author":"Cheng","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R6-20260422","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/thx.2003.019224","article-title":"Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection","volume":"59","author":"Breen","year":"2004","journal-title":"Thorax"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.5588\/ijtld.15.0257","article-title":"Late paradoxical lymph node enlargement during and after anti-tuberculosis treatment in non-HIV-infected patients","volume":"19","author":"Yu","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"R8-20260422","first-page":"367","article-title":"Health profession standards of the people\u2019s republic of China classification of tuberculosis: WS 196-2017","volume":"17","author":"Wang","year":"2018","journal-title":"Chin J Infect Control"},{"key":"R9-20260422","first-page":"59","article-title":"Diagnosis for pulmonary tuberculosis (WS288\u20102017)","volume":"3","year":"2018","journal-title":"Electr J Emerg Infect Dis"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3389\/fpsyg.2013.00863","article-title":"Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for t-tests and ANOVAs","volume":"4","author":"Lakens","year":"2013","journal-title":"Front Psychol"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1473-3099(08)70184-1","article-title":"Tuberculosis-associated immune reconstitution inflammatory syndrome: Case definitions for use in resource-limited settings","volume":"8","author":"Meintjes","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"e1997","DOI":"10.1097\/MD.0000000000001997","article-title":"Paradoxical manifestation is common in HIV-negative tuberculous meningitis","volume":"95","author":"Tai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijid.2018.11.366","article-title":"Paradoxical reaction in HIV-negative tuberculous meningitis patients with spinal involvement","volume":"79","author":"Liu","year":"2019","journal-title":"Int J Infect Dis"},{"key":"R17-20260422","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1186\/s12879-016-1816-4","article-title":"Determinants of treatment-related paradoxical reactions during anti-tuberculosis therapy: A case control study","volume":"16","author":"Brown","year":"2016","journal-title":"BMC Infect Dis"},{"key":"R18-20260422","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jinf.2013.07.022","article-title":"Incidence and outcomes of paradoxical lymph node enlargement after anti-tuberculosis therapy in non-HIV patients","volume":"67","author":"Park","year":"2013","journal-title":"J Infect"},{"key":"R19-20260422","first-page":"1290","article-title":"Paradoxical response during anti-tuberculosis treatment in HIV-negative patients with pulmonary tuberculosis","volume":"11","author":"Cheng","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"R20-20260422","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(83)92377-2","article-title":"Unexpected deaths in pulmonary tuberculosis","volume":"1","author":"Clague","year":"1983","journal-title":"Lancet"},{"key":"R21-20260422","first-page":"201","article-title":"Paradoxical response with increased tumor necrosis factor-\u03b1 levels to anti-tuberculosis treatment in a patient with disseminated tuberculosis","volume":"20","author":"Watanabe","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"R22-20260422","doi-asserted-by":"crossref","first-page":"e00658","DOI":"10.1002\/rcr2.658","article-title":"Relapsing paradoxical reaction in miliary tuberculosis: A case report and literature review","volume":"8","author":"Mobeireek","year":"2020","journal-title":"Respirol Case Rep"},{"key":"R23-20260422","first-page":"240","article-title":"Lipoarabinomannan from Mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages","volume":"76","author":"Moreno","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"R24-20260422","doi-asserted-by":"crossref","first-page":"341","DOI":"10.5588\/ijtld.13.0565","article-title":"Clinical significance of residual lesions in chest computed tomography after anti-tuberculosis treatment","volume":"18","author":"Seon","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"R25-20260422","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1752-1947-7-72","article-title":"Systemic lymph node tuberculosis presenting with an aseptic psoas abscess caused by a paradoxical reaction after nine months of antituberculosis treatment: A case report","volume":"7","author":"Yamada","year":"2013","journal-title":"J Med Case Rep"},{"key":"R26-20260422","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5152\/dir.2014.14212","article-title":"Thoracic manifestations of paradoxical immune reconstitution inflammatory syndrome during or after antituberculous therapy in HIV-negative patients","volume":"21","author":"Pornsuriyasak","year":"2015","journal-title":"Diagn Interv Radiol"},{"key":"R27-20260422","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.medj.2022.07.001","article-title":"Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: A case series","volume":"3","author":"van Arkel","year":"2022","journal-title":"Med"},{"key":"R28-20260422","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1086\/598504","article-title":"Adalimumab treatment of life-threatening tuberculosis","volume":"48","author":"Wallis","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R30-20260422","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4103\/ijmy.ijmy_75_20","article-title":"Adverse drug reactions of anti-tuberculosis treatment among children with tuberculosis","volume":"9","author":"Laghari","year":"2020","journal-title":"Int J Mycobacteriol"},{"key":"R31-20260422","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4103\/ijmy.ijmy_78_22","article-title":"Treatment and management of hypersensitivity reactions developed against anti-tuberculosis drug","volume":"11","author":"Katran","year":"2022","journal-title":"Int J Mycobacteriol"},{"key":"R32-20260422","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(19)31882-3","article-title":"Management of drug-resistant tuberculosis","volume":"394","author":"Lange","year":"2019","journal-title":"Lancet"},{"key":"R33-20260422","doi-asserted-by":"crossref","first-page":"2003300","DOI":"10.1183\/13993003.03300-2020","article-title":"World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update","volume":"57","author":"Mirzayev","year":"2021","journal-title":"Eur Respir J"},{"key":"R34-20260422","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical practice guidelines: Treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R35-20260422","doi-asserted-by":"crossref","first-page":"299","DOI":"10.7861\/clinmedicine.12-3-299","article-title":"Cavitating pulmonary tuberculosis: A global challenge","volume":"12","author":"Bothamley","year":"2012","journal-title":"Clin Med (Lond)"},{"key":"R38-20260422","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/s13104-020-05369-8","article-title":"Bacterial etiology of sputum from tuberculosis suspected patients and antibiogram of the isolates","volume":"13","author":"Regmi","year":"2020","journal-title":"BMC Res Notes"},{"key":"R39-20260422","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1128\/CMR.00096-15","article-title":"Microbiome changes during tuberculosis and antituberculous therapy","volume":"29","author":"Hong","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"R40-20260422","first-page":"e37664","article-title":"Identification of fungal isolates in patients with pulmonary tuberculosis treated at a tertiary care hospital","volume":"15","author":"Muni","year":"2023","journal-title":"Cureus"},{"key":"R41-20260422","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4103\/0973-029X.185913","article-title":"Prevalence and characterization of opportunistic candidal infections among patients with pulmonary tuberculosis","volume":"20","author":"Astekar","year":"2016","journal-title":"J Oral Maxillofac Pathol"},{"key":"R42-20260422","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/ijmy.ijmy_1_20","article-title":"Fungal isolates findings of sputum samples in new and previously treated cases of pulmonary tuberculosis in dr. Soetomo hospital Surabaya, Indonesia","volume":"9","author":"Soedarsono","year":"2020","journal-title":"Int J Mycobacteriol"},{"key":"R43-20260422","doi-asserted-by":"crossref","first-page":"951","DOI":"10.62347\/CBWV2685","article-title":"Characteristics and risk factors of pulmonary fungal infection in patients with pulmonary tuberculosis","volume":"17","author":"Wu","year":"2025","journal-title":"Am J Transl Res"},{"key":"R44-20260422","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4103\/ijmy.ijmy_98_20","article-title":"Diagnosis of atypical mycobacterial and fungal coinfection","volume":"9","author":"Jimeno","year":"2020","journal-title":"Int J Mycobacteriol"},{"key":"R45-20260422","first-page":"6234","article-title":"Differences in CT imaging signs between patients with tuberculosis and those with tuberculosis and concurrent lung cancer","volume":"14","author":"Tang","year":"2022","journal-title":"Am J Transl Res"},{"key":"R46-20260422","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1017\/S0950268822000176","article-title":"Comparison of clinical and imaging features between pulmonary tuberculosis complicated with lung cancer and simple pulmonary tuberculosis: A systematic review and meta-analysis","volume":"150","author":"Sun","year":"2022","journal-title":"Epidemiol Infect"},{"key":"R47-20260422","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4103\/ijmy.ijmy_89_21","article-title":"Tuberculosis presenting as metastatic lung cancer","volume":"10","author":"Saleemi","year":"2021","journal-title":"Int J Mycobacteriol"},{"key":"R49-20260422","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cmi.2017.12.003","article-title":"Infectious complications associated with the use of immune checkpoint inhibitors in oncology: Reactivation of tuberculosis after anti PD-1 treatment","volume":"24","author":"Picchi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"R50-20260422","doi-asserted-by":"crossref","first-page":"e002960","DOI":"10.1136\/jitc-2021-002960","article-title":"Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: A nationwide observational study","volume":"9","author":"Bae","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R51-20260422","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1186\/s12885-018-4889-1","article-title":"Efficacy and safety of concurrent anti-cancer and anti-tuberculosis chemotherapy in cancer patients with active Mycobacterium tuberculosis: A retrospective study","volume":"18","author":"Hirashima","year":"2018","journal-title":"BMC Cancer"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_33_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:56:21Z","timestamp":1786647381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_33_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_33_25","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2025-02-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}